Bringing Cannabinoid Diagnostics to Personalized Cancer Care
Cannabics Pharmaceuticals Inc. (CNBX), a U.S-based public company, is dedicated to the development of personalized diagnostic tools, aimed to provide supportive data for practitioners and patients regarding cannabinoid based therapy. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations. Cannabics engages in delivering the maximum amount of supportive data for cancer patients and their doctors, utilizing advanced screening systems and personalized bioinformatics tools.
Cannabics is developing diagnostic procedures designated for delivering precise data regarding the individual patients treatment choices for treating cancer and its side-effects . We are currently engaged in a clinical study, in Israel, on Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients. Our path to fight cancer is based on the engagement with technology tools such as High Throughput Screening Technology (HTS) on cancer cell lines and CTC drug sensitivity tests on liquid biopsies.